The first evidence of clinical benefit of vaccination for patients with metastatic melanoma came from a prospective randomized phase III trial, conducted with stage IV or locally advanced stage III cutaneous melanoma, HLA A0201+ patients, without brain metastases who received high-dose IL-2 (720.000 IU/kg/dose) as the control group and a gp100 peptide containing a modified 209-217 (210M) epitope + montanide ISA followed by high-dose IL-2 as the experimental arm [80]. Here, IL2 is linked to cutaneous melanoma.